RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th

Rhea-AI Summary

RenovoRx (Nasdaq: RNXT) announced that CEO Shaun Bagai will present at the iAccess Alpha Virtual Best Ideas Winter Investment Conference on December 9, 2025 at 12:30 P.M. ET. The presentation will cover commercial progress and market adoption of RenovoCath, recent clinical and scientific program updates, and support for investigator‑initiated trials.

The company reported year‑to‑date revenue of approximately $900,000 through September 30, 2025, and will discuss the ongoing Phase III TIGeR‑PaC trial and a post‑marketing registry capturing real‑world safety and effectiveness data. A replay and webcast will be available on the company investor site.

News Market Reaction

-6.59%

1 alert

-6.59% News Effect

On the day this news was published, RNXT declined 6.59%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

YTD Revenue: approximately $900,000 Q3 2025 Revenue: $266,000 Cash Balance: $10.0 million +5 more

8 metrics

YTD Revenue approximately $900,000 Year-to-date through September 30, 2025, from RenovoCath sales

Q3 2025 Revenue $266,000 Quarter ended September 30, 2025

Cash Balance $10.0 million As of September 30, 2025 per Q3 10-Q

Q3 Net Loss $2.9 million Quarter ended September 30, 2025

ATM Capacity $3,723,029 Capital on Demand Sales Agreement via JonesTrading (8-K/424B5)

Shelf Registration $50,000,000 Form S-3 mixed securities shelf filed November 14, 2025

Shares Outstanding 36,649,916 As of November 12, 2025 per S-3 and 10-Q

Insider Purchase 22,000 shares at $0.80 CMO open-market buys on November 21 and 24, 2025 (Form 4)

Market Reality Check

Price: $0.9958 Vol: Volume 190,061 is at 0.58...

low vol

$0.9958 Last Close

Volume Volume 190,061 is at 0.58x the 20-day average of 329,321 ahead of the conference update. low

Technical Shares at $0.9929 are trading below the 200-day MA of $1.11, with the stock 41.25% under its 52-week high and 41.72% above its 52-week low.

Peers on Argus

RNXT was modestly higher pre-news, while peers showed mixed moves: PSTV +7.14%, ...

1 Up

RNXT was modestly higher pre-news, while peers showed mixed moves: PSTV +7.14%, RENB +19.33%, TELO +5.71%, TPST +1.94%, and BCAB -0.86%. Momentum scanner only flagged one biotech peer, suggesting stock-specific dynamics rather than a broad sector leg.

Common Catalyst Select biotech peers also had clinical and conference-related headlines, but RNXT’s news is a company-focused investor conference presentation.

Historical Context

5 past events · Latest: Dec 01 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 01	Investor conference update	Neutral	-6.6%	CEO scheduled to present commercial and clinical updates at iAccess Alpha.
Nov 19	Investor conference update	Neutral	-6.4%	CEO to present at AGP virtual showcase on commercialization and trials.
Nov 13	Earnings and business update	Negative	-2.6%	Q3 results showed early revenue, continued losses, and cash constraints.
Nov 06	SAB strengthening	Positive	-6.2%	Pancreatic cancer expert added to Scientific Advisory Board endorsing TAMP.
Nov 04	Conference participation	Positive	-6.4%	CEO to provide RenovoCath commercialization and TIGeR-PaC trial update.

Pattern Detected

Recent RNXT news — largely commercial, clinical, and conference updates — has often been followed by negative 24-hour price reactions, even when the content itself appears constructive or neutral.

Recent Company History

Over the past month, RNXT has reported Q3 2025 results, expanded its conference presence, and strengthened its scientific advisory board. Earnings showed early RenovoCath traction with $266,000 in Q3 revenue and roughly $900,000 year-to-date, but also ongoing losses and a need for additional financing. Multiple conference announcements highlighted commercialization of RenovoCath and progress in the Phase III TIGeR-PaC trial and post-marketing registry. Despite generally constructive operational updates, the stock saw negative 24-hour reactions after each prior event, framing today’s investor conference update within a pattern of cautious trading.

Regulatory & Risk Context

Active S-3 Shelf · $50,000,000

Shelf Active

Active S-3 Shelf Registration 2025-11-14

$50,000,000 registered capacity

RNXT filed a Form S-3 shelf on 2025-11-14 to register up to $50,000,000 of mixed securities, supporting working capital, the Phase III TIGeR-PaC study, and RenovoCath commercialization. Shelf usage has begun, with at least one 424B5 prospectus supplement filed for an at-the-market stock offering. This structure gives the company flexibility to raise capital over time.

Market Pulse Summary

The stock moved -6.6% in the session following this news. A negative reaction despite neutral confer...

Analysis

The stock moved -6.6% in the session following this news. A negative reaction despite neutral conference news would fit RNXT’s recent pattern, where commercial and clinical updates around RenovoCath and the Phase III TIGeR-PaC study were followed by 24-hour declines. The newly filed $50,000,000 shelf and at-the-market structure, alongside ongoing net losses noted in Q3, may have kept financing risk in focus. Historical reactions suggest traders often faded even constructive announcements, reinforcing downside sensitivity to perceived dilution.

Key Terms

Phase III, intra-arterial, gemcitabine, locally advanced pancreatic cancer, +4 more

8 terms

Phase III medical

"including the ongoing Phase III TIGeR-PaC clinical trial for intra-arterial"

A Phase III trial is the late-stage clinical study that tests whether a medical treatment works and is safe in a large group of patients, often comparing it to standard care. Think of it as a final dress rehearsal or full-scale road test before regulators decide on approval; positive or negative results strongly influence a drug maker’s chance to sell the treatment, future revenue, and investment risk.

intra-arterial medical

"Phase III TIGeR-PaC clinical trial for intra-arterial gemcitabine delivered"

Injection or placement directly into an artery — the blood vessel that carries oxygen-rich blood away from the heart — so medicine, diagnostic agents, or devices reach a specific organ or tumor quickly and in higher concentration. For investors, intra-arterial approaches can change a treatment’s effectiveness, safety profile, regulatory pathway and device needs, which affects clinical adoption, market size and revenue potential much like delivering water straight into a main pipe reaches the target faster than sprinkling it on the surface.

gemcitabine medical

"clinical trial for intra-arterial gemcitabine delivered via RenovoCath (IAG)"

Gemcitabine is a chemotherapy drug that works by interfering with cancer cells’ ability to copy their DNA, which slows or stops tumor growth. Investors watch it because clinical trial results, regulatory approvals, patent status, or manufacturing and supply issues for a widely used cancer medicine can materially affect a drugmaker’s sales, partnerships, and stock value—think of it as a key product whose market performance can move a company.

locally advanced pancreatic cancer medical

"IAG) in locally advanced pancreatic cancer (LAPC), and progress in its"

A stage of pancreatic cancer where the tumor has grown beyond the pancreas into nearby tissues or blood vessels but has not spread to distant organs, often making surgical removal difficult or impossible. Investors pay attention because this group of patients represents a large, urgent market for new treatments and clinical trials: successes or failures in this setting can quickly change a drug’s commercial prospects, regulatory path, and revenue outlook, much like a firefighting tool that’s in high demand when a blaze reaches critical structural parts of a building.

post-marketing registry medical

"progress in its post-marketing registry study capturing real-world data on"

A post-marketing registry is an organized database that collects information on how a medical product performs in everyday use after it has been approved, tracking real-world safety, side effects and longer-term effectiveness. Investors pay attention because registry findings can trigger label changes, additional studies, or regulatory actions that affect sales, legal exposure and the long-term commercial outlook—think of it as a public maintenance log that can reveal hidden problems or benefits over time.

solid tumors medical

"real-world data on the safety and effectiveness of RenovoCath in patients with solid tumors."

Solid tumors are abnormal masses of tissue that form when cells in organs or glands grow uncontrollably, like a dense knot in a garden plant rather than something spread through the water. For investors, they matter because treatments, diagnostics and surgeries targeting solid tumors drive large clinical programs, regulatory reviews and potential revenue streams; success or failure in treating these tumors can significantly affect a company’s drug pipeline, valuation and market opportunity.

oligometastatic pancreatic cancer medical

"investigator-initiated trials in borderline resectable and oligometastatic pancreatic cancer."

Oligometastatic pancreatic cancer is a form of pancreatic tumor that has spread from its original site but only to a few distant locations, more like a few isolated outposts instead of an army occupying many territories. That limited pattern matters to investors because it often allows different treatment approaches—such as targeted radiation, surgery, or focused systemic therapies—that can alter outcomes, affect the design and likelihood of success in clinical trials, and influence the commercial potential for new therapies and diagnostic tools.

Trans-Arterial Micro-Perfusion medical

"broaden the application for RenovoRx’s TAMP™ (Trans-Arterial Micro-Perfusion) therapy"

A targeted medical delivery technique that uses tiny catheters inserted into an artery to drip or spray a drug or therapeutic agent directly into the small blood vessels feeding a specific organ or tumor. Like watering the roots of a single plant instead of the whole garden, it concentrates treatment where needed, which can improve effectiveness and reduce side effects—important for investors because it affects clinical success, regulatory risk, and commercial potential.

AI-generated analysis. Not financial advice.

MOUNTAIN VIEW, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (Nasdaq: RNXT) (“RenovoRx” or “the Company”), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath^®, a novel, FDA-cleared drug-delivery device, today announced that Chief Executive Officer Shaun Bagai will present at the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025, held on December 9-10, 2025. Mr. Bagai’s presentation will be held on Tuesday, December 9^th at 12:30 P.M. ET.

Mr. Bagai will share updates on RenovoRx’s continued commercial efforts and market traction, underscored by growing clinical demand and adoption of RenovoCath as a standalone, targeted drug-delivery device across both new and repeat customers. RenovoRx recently reported third quarter of 2025 financial results, demonstrating progress as year-to-date (end of September 30, 2025) revenue grew to approximately $900,000.

He will also discuss recent advancements in the Company’s clinical research and scientific programs, including the ongoing Phase III TIGeR-PaC clinical trial for intra-arterial gemcitabine delivered via RenovoCath (IAG) in locally advanced pancreatic cancer (LAPC), and progress in its post-marketing registry study capturing real-world data on the safety and effectiveness of RenovoCath in patients with solid tumors. In addition, he will also highlight the ongoing support of investigator-initiated trials in borderline resectable and oligometastatic pancreatic cancer. These capital-efficient studies will provide meaningful data that create the potential to further broaden the application for RenovoRx’s TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform.

iAccess Alpha Virtual Conference Details:
Date: December 9-10, 2025
Presentation Date and Time: Tuesday, December 9^th at 12:30 P.M. ET
Webcast: https://ir.renovorx.com/news-events/ir-calendar-events

To schedule a one-on-one investor meeting with Mr. Bagai, please contact KCSA Strategic Communications at RenovoRx@KCSA.com.

A replay of Mr. Bagai’s presentation will be available on the Company’s website at https://ir.renovorx.com/news-events following the event.

About RenovoCath
Based on its FDA clearance, RenovoCath^® is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding our RenovoCath Instructions for Use (“IFU”), please see: IFU-10004-Rev.-G-Universal-IFU.pdf.

About RenovoRx, Inc.
RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath^®, a novel, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents.

RenovoRx is in the early stages of actively commercializing its TAMP technology and FDA-cleared RenovoCath as a stand-alone device. In December 2024, RenovoRx announced the receipt of its first commercial purchase orders for RenovoCath devices, and for the first nine months of 2025, approximately $900,000 of revenues were generated from RenovoCath sales. Several customers have already initiated repeat orders in parallel to RenovoRx expanding the number of medical institutions initiating new RenovoCath orders, including several esteemed, high-volume National Cancer Institute-designated centers. To meet and satisfy the anticipated demand, RenovoRx will continue to actively explore further revenue-generating activity, either on its own or in tandem with a medical device commercial partner.

RenovoRx is also evaluating its novel drug-device combination oncology product candidate (intra-arterial gemcitabine delivered via RenovoCath, known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division of the FDA) under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. IAG utilizes RenovoCath, the Company’s patented, FDA-cleared drug-delivery device, indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.

The IAG combination product candidate, which is enabled by the RenovoCath device, is currently under investigation and has not been approved for commercial sale. RenovoCath with gemcitabine received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which provides seven years of market exclusivity upon new drug application approval by the FDA.

For more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn, and X.

Cautionary Note Regarding Forward-Looking Statements
This press release, the presentation described herein, and statements of the Company’s management made in connection therewith contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding (i) our clinical trials and studies, (ii) the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases, and (iii) our efforts to commercialize our RenovoCath and our TAMP technology. Statements that are not purely historical are forward-looking statements. The forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control, and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections, and statements relating to our research and development plans, intellectual property development, clinical trials, our therapy platform, business plans, financing plans, objectives, and expected operating results, which are based on current expectations and assumptions that are subject to known and unknown risks and uncertainties that may cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These statements may be identified using words such as “may,” “expects,” “plans,” “aims,” “anticipates,” “believes,” “forecasts,” “estimates,” “intends,” and “potential,” or the negative of these terms or other comparable terminology regarding RenovoRx’s expectations strategy, plans, or intentions, although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated by such statements, including, among other things: (i) the risk that our exploration of commercial opportunities for our TAMP technology may not lead to viable, revenue generating operations; (ii) circumstances which would adversely impact our ability to efficiently utilize our cash resources on hand or raise additional funding-; (iii) the timing of the initiation, progress, and potential results (including the results of interim analyses) of our preclinical studies, clinical trials, and our research programs; (iv) the possibility that interim results may not be predictive of the outcome of our clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate-;(v) that the applicable regulatory authorities may disagree with our interpretation of the data-, research, and clinical development plans and timelines, and the regulatory process for our product candidates; (vi) future potential regulatory milestones for our product candidates, including those related to current and planned clinical studies; (vii) our ability to use and expand our therapy platform to build a pipeline of product candidates; (viii) our ability to advance product candidates into, and successfully complete, clinical trials; (ix) the timing or likelihood of regulatory filings and approvals; (x) our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; (xi) the commercialization potential of our product candidates, if approved; (xii) our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; (xiii) future strategic arrangements and/or collaborations and the potential benefits of such arrangements; (xiv) our estimates regarding expenses, future revenue, capital requirements, and needs for additional financing and our ability to obtain additional capital; (xv) the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; (xvi) our ability to retain the continued service of our key personnel and to identify, and hire and retain additional qualified personnel; (xvii) the implementation of our strategic plans for our business and product candidates; (xviii) the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates, and research programs; (xix) our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; (xx) the pricing, coverage, and reimbursement of our product candidates, if approved; and (xxi) developments relating to our competitors and our industry, including competing product candidates and therapies. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that we file from time to time with the Securities and Exchange Commission.

Forward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law.

Contact:
KCSA Strategic Communications
Valter Pinto or Jack Perkins
T: 212-896-1254
RenovoRX@KCSA.com

FAQ

When will RenovoRx (RNXT) present at the iAccess Alpha Winter Investment Conference 2025?

CEO Shaun Bagai will present on December 9, 2025 at 12:30 P.M. ET.

What topics will RenovoRx (RNXT) cover in the December 9, 2025 presentation?

Updates on commercial traction of RenovoCath, year‑to‑date revenue, the Phase III TIGeR‑PaC trial, post‑marketing registry data, and investigator‑initiated trials.

How much revenue did RenovoRx (RNXT) report year‑to‑date through September 30, 2025?

RenovoRx reported year‑to‑date revenue of approximately $900,000 through September 30, 2025.

Where can investors watch the RenovoRx (RNXT) presentation and replay for December 2025?

The live webcast and replay will be available on RenovoRx's investor events page at https://ir.renovorx.com/news-events.

Will RenovoRx (RNXT) discuss clinical trials during the December 9, 2025 presentation?

Yes. The CEO will discuss the ongoing Phase III TIGeR‑PaC intra‑arterial gemcitabine trial and a post‑marketing registry for RenovoCath.